AstraZeneca and the company “R-Pharm” announced cooperation in the field of production in Russia of recombinant adenoviral vaccines to prevent infection COVID-19 caused by a virus SARS-CoV-2.
In the framework of cooperation is planned to organize production of the vaccine AZD1222 from COVID-19 if clinical studies are successful.
In Russia transferred to the cell line and the adenoviral vector, it is planned to produce the antigen and produce a finished dosage form. In this case Russia will become one of the hubs for the production and supply vaccines to international markets. Will export more than 30 countries around the world, including the middle East, the Balkans and CIS countries.
In may, the company AstraZeneca has signed a partnership with the University of Oxford for the development, production and delivery of vaccines AZD1222 from COVID-19. As previously announced, AstraZeneca has committed itself to supply more than 2 billion doses of vaccine, the company builds several parallel supply chains with partners around the world to ensure broad and equitable global access to vaccines to as many countries on a nonprofit basis during the period of the pandemic.
Currently, worldwide research is being conducted the late stage of phase II/III, which are designed to determine how well the vaccine will protect people from COVID-19, and to evaluate the safety and immune response in humans in different age ranges and at different doses. The company AstraZeneca is aware that the vaccine may not work, but is configured to accelerate the development of clinical programs and increased production volumes at risk.
AZD1222 was developed by Jenner Institute of Oxford University and the Oxford study group of vaccines. The vaccine uses a replication defective vector based on a weakened adenovirus that causes infection in chimpanzees, which contains the genetic material of the spinous protein of SARS-CoV-2. After vaccination, the synthesis of spiky surface protein, which leads to the formation of an immune response to COVID-19 with possible subsequent infected by this virus.